The treatment of SLC derived from two human GBM cell lines (U87MG and U251) with ATRA inhibited the expression of stemness markers such as CD133 and Sox2, and reversed the suppression caused by NSPc1 on RDH16, allowing cell differentiation to take place [19]. The gene discussed is PROM1; the disease is glioblastoma.